TRex Bio (Venture)
Funding Details
Awarder
Inbox
Date Award
January 27, 2026
Vertical
Biotechnology
Funding URL
View Funding Page
Funding Amount
$50,000,000
Company Info
Organizations Involved
Eli Lilly and Company, Johnson & Johnson Development Corporation (JJDC), Pfizer Venture Investments
Market
Immunotherapy for autoimmune and inflammatory diseases
Coinvestors
Affinity Asset Advisors, Alexandria Venture Investments, Avego Bioscience Capital, Balyasny Asset Management, Delos Capital, Eli Lilly and Company, Janus Henderson Investors, Johnson & Johnson Development Corporation (JJDC), Pfizer Venture Investments, Polaris Partners, SV Health Investors
Company Description

TRexBio is a clinical-stage biotechnology company discovering and developing immunoregulatory medicines based on tissue Treg biology by leveraging cutting-edge computational biology tools, a focus on human tissue, and deep immunobiology expertise. The company's Deep Biology Platform maps human tissue Treg behavior to disease processes to identify and characterize novel targets for therapeutic intervention in autoimmune and inflammatory diseases.

Links
Website
Back to HomeBack to Biotechnology DealsView Funding Announcement